Mostrar el registro sencillo del ítem

Trehalose as a promising therapeutic candidate for the treatment of Parkinson's disease

dc.contributor.authorKhalifeh M.
dc.contributor.authorBarreto G.E.
dc.contributor.authorSahebkar A.
dc.date.accessioned2020-09-02T22:21:07Z
dc.date.available2020-09-02T22:21:07Z
dc.date.issued2019
dc.identifier10.1111/bph.14623
dc.identifier.citation176, 9, 1173-1189
dc.identifier.issn00071188
dc.identifier.urihttps://hdl.handle.net/20.500.12728/5002
dc.descriptionParkinson's disease (PD) is a progressive movement disorder resulting primarily from loss of nigrostriatal dopaminergic neurons. PD is characterized by the accumulation of protein aggregates, and evidence suggests that aberrant protein deposition in dopaminergic neurons could be related to the dysregulation of the lysosomal autophagy pathway. The therapeutic potential of autophagy modulators has been reported in experimental models of PD. Trehalose is a natural disaccharide that has been considered as a new candidate for the treatment of neurodegenerative diseases. It has a chaperone-like activity, prevents protein misfolding or aggregation, and by promoting autophagy, contributes to the removal of accumulated proteins. In this review, we briefly summarize the role of aberrant autophagy in PD and the underlying mechanisms that lead to the development of this disease. We also discuss reports that used trehalose to counteract the neurotoxicity in PD, focusing particularly on the autophagy promoting, protein stabilization, and anti-neuroinflammatory effects of trehalose. © 2019 The British Pharmacological Society
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc.
dc.titleTrehalose as a promising therapeutic candidate for the treatment of Parkinson's disease
dc.typeReview


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85063433364.pdf
Tamaño:
2.083Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem